MRNS - Marinus Pharmaceuticals, Inc.
| Previous Close | 4.6500 |
| Open | 4.5900 |
| Bid | 4.4800 x 1100 |
| Ask | 4.7300 x 1300 |
| Day's Range | 4.4700 - 4.6800 |
| 52 Week Range | 2.3600 - 10.5400 |
| Volume | 298,705 |
| Avg. Volume | 744,096 |
| Market Cap | 236.496M |
| Beta (3Y Monthly) | 4.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9840 |
| Earnings Date | Jul 30, 2018 - Aug 3, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.06 |
- Associated Press•18 days ago
Marinus Pharmaceuticals: 1Q Earnings Snapshot
On a per-share basis, the Radnor, Pennsylvania-based company said it had a loss of 24 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
- GlobeNewswire•18 days ago
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
Marinus Pharmaceuticals, Inc. (MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the first quarter ended March 31, 2019. “In 2019, Marinus continues to advance its ganaxolone clinical programs for PPD, orphan pediatric genetic epilepsies and refractory status epilepticus,” said Dr. Scott Braunstein, executive chairman of Marinus. “We have seen strong enrollment trends across our Phase 2 programs and have decided to take advantage of this interest and increase the size of all three of these studies with minimal impact to timelines. Both PPD studies are fully enrolled and we will be expanding our RSE cohorts to include up to 20 patients. As a result, we expect data from the PPD studies in the first half of the third quarter and data from the RSE study by the end of the third quarter.
- Simply Wall St.•23 days ago
How Much Of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Do Institutions Own?
Every investor in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller...
- Zacks•2 months ago
Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options
Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.
- Zacks•2 months ago
Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings
Oracle (ORCL) is benefiting from increasing adoption of its product portfolio and synergies from strategic buyouts.
- Zacks•2 months ago
Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing?
Broadcom (AVGO) extensive product portfolio is likely to positively impact the to-be-reported quarter's results.
- GlobeNewswire•2 months ago
Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results
Marinus Pharmaceuticals, Inc. (MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the year ended December 31, 2018. “2018 was a pivotal year for Marinus, kicking off the first-ever single pivotal Phase 3 study in children with CDKL5 deficiency disorder, and reporting positive results from Part 1 of our Magnolia Study with IV ganaxolone in women with postpartum depression,” said Christopher M. Cashman, CEO of Marinus. Dr. Scott Braunstein, Executive Chairman of Marinus commented, “Through the multiple clinical studies conducted to date, we have shown that ganaxolone is safe, well-tolerated and effective in reducing seizures, anxiety and depression.
- GlobeNewswire•2 months ago
Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that it is initiating a single global pivotal Phase 3 clinical study (Violet Study) evaluating oral ganaxolone in children with PCDH19-related epilepsy (PCDH19-RE), a rare genetic epilepsy. If successful, the Violet Study is intended to support the regulatory filings for approval of ganaxolone in this underserved and refractory patient population. The Violet Study is a global, double-blind, randomized, placebo-controlled pivotal Phase 3 clinical study evaluating ganaxolone in children with PCDH19-RE.
- Benzinga•2 months ago
Jefferies Sees Opportunity In Marinus Pharmaceuticals: 4 Reasons Why
Shares of Marinus Pharmaceuticals Inc (NASDAQ: MRNS ), a micro-cap biotech focused on therapies for neuropsychiatric disorders, are likely to see upside amid some key near-term events, according to Jefferies. ...
- GlobeNewswire•2 months ago
Marinus Pharmaceuticals to Present at the Cowen Healthcare Conference
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Edward Smith, Chief Financial Officer, will present a company overview at the 39th Annual Cowen and Company Healthcare Conference on Monday, March 11, 2019 at 4:10 p.m. ET. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.
- American City Business Journals•3 months ago
Main Line biopharm CEO stepping down
A Main Line biopharmaceutical company is searching for a new chief executive officer. Marinus Pharmaceuticals of Radnor said Tuesday its CEO, Christopher Cashman, is leaving the company effective March 18 to pursue other opportunities. In an interview with the Philadelphia Business Journal, Cashman said he would classify his departure as a "mutual" decision.
- GlobeNewswire•3 months ago
Marinus Announces Leadership Transition
Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that chief executive officer, Christopher M. Cashman, will leave the Company to pursue other opportunities in the life science industry effective March 18, 2019. Scott Braunstein, M.D., currently a director on the Company’s Board, has been appointed executive chairman. Marinus has retained an executive search firm to identify Mr. Cashman’s successor as CEO.
- GlobeNewswire•3 months ago
Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Christopher M. Cashman, Chief Executive Officer will present a company overview at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 3:00 p.m. ET. The conference will take place in New York. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.
- InvestorPlace•3 months ago
Zynerba Stock Is Marijuana-Adjacent Play Worth a Look
Lately, the pharmaceutical companies are trying to use cannabis-based therapies to treat all sorts of medical conditions. Zynerba (NASDAQ:ZYNE) is another contender in this increasingly-crowded field. Whether that's a good or bad thing for Zynerba stock remains to be seen.After all, they appear to have a pretty interesting play within the space. Their ZYN002 drug candidate is, according to the company, "the first and only pharmaceutically-produced CBD formulated as a permeation‑enhanced gel for transdermal delivery".They are running studies on this CBD gel for a variety of conditions. They are investigating treatments for Fragile X, Tourette's, and seizures, among other conditions.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Monster Growth Stocks to Buy for 2019 and Beyond Understanding The Fragile X Syndrome Therapeutic LandscapeFragile X Syndrome is a relatively rare condition occurring in roughly 1 out of every 4,000 boys and 1 out of every 8,000 girls. Researchers believe that the condition is caused by a DNA defect. Fragile X often presents symptoms in children by age 2 including intellectual disability and physical characteristics such as long face and a prominent jaw.It is sometimes a complicated diagnosis as Fragile X can look like other developmental disorders. Many Fragile X children have Attention Deficit Disorder. Additionally, many exhibit features of autism disorders. Furthermore, a significant number of Fragile X patients have frequent seizures.This leads to an interesting position for Zynerba. The company states that there are no approved drug therapies for Fragile X. However, it notes that doctors use various drugs off-label to treat various Fragile X symptoms. That makes sense, as there are treatments for things such as seizures.Directly, as far as competition, Zynerba notes that Neuren Pharmaceuticals, Ovid Therapeutics (NASDAQ:OVID) and Marinus Pharmaceuticals (NASDAQ:MRNS) are all active in the research space seeking a treatment directly for Fragile X syndrome.That's not all. Zynerba has focused on the treatment of seizures in particular. Within that particular space, it faces cannabinoid-based competition on several fronts. GW Pharma (NASDAQ:GWPH), with its more than $4 billion market cap, is targeting this space and is widely thought of as a leader in cannabinoid research.Additionally, Insys (NASDAQ:INSY) is researching CBDs for seizures and infantile spasms as well. So, should Zynerba's ZYN002 be a clinical success, it won't necessarily be the first or best therapy that reaches the market. Why Zynerba Stock Popped RecentlyOn January 28th, Zynerba stock shot up 30% to reach $4.80. In subsequent days, it rallied further, reaching as high as the $6 mark. What happened on Jan. 28 that set the rally in motion? There doesn't appear to be much in the way of hard news, but the company did give a high-profile presentation and it appears this set investor enthusiasm in motion.In this presentation, the company confirmed that things are moving along as planned for its combination Phase 2/3 CONNECT trail for Fragile X syndrome. Zynerba also expects to release results for its Phase 2 trial for developmental and epileptic encephalopathies in the latter half of 2019.To add to that, Zynerba remains in reasonably strong financial position. The company reported $59.8 million in cash as of December 31st, 2018.Given its current burn rate, that should give Zynerba funds to continue its current research through the second half of 2020. While Zynerba will have to raise more funds at some point, it still has plenty of time to deliver its crucial trial results later in 2019 before going back to the market for more money. The CBD FactorIt's difficult to consider ZYNE stock without thinking about the X factor here: investor enthusiasm for marijuana-related stocks. Since late December the Alternative Harvest (NYSEARCA:MJ) marijuana ETF has ripped 50% higher off the lows. Stocks like Aphria (NYSE:APHA) and Canopy Growth (NYSE:CGC) are soaring almost every day.Zynerba itself hadn't participated in this enthusiasm, at least not until recently. However, that may be changing. Recently, famous TV host Jim Cramer talked up so-called "marijuana-adjacent" biotech firms as stocks with big potential in 2019.Cramer said:"These are not pot companies. They are drug companies focused on developing artificial cannabinoids that mimic what cannabis does to your body […] As we get more and more data showing the efficacy of medicinal marijuana, I think more investors will embrace actual medicines that do the same thing as marijuana, but they do it more reliably."With ZYNE stock, you are getting a call option on this thesis playing out later in 2019. Zynerba Stock VerdictI rarely invest in clinical stage biotech companies. It's a difficult industry; far more companies fail than succeed. Be careful with these sorts of stocks and don't invest more than you can afford to lose.That said, Zynerba has an interesting drug candidate, and is certainly positioned in a hot sector of the market. With plenty of cash to make it into mid-2020, and key data coming before then, ZYNE stock has plenty of speculative value for active traders.One upcoming catalyst to watch out for. On February 11th, CEO Armando Anido will be giving a presentation at the 2019 BIO CEO and Investor Conference. With ZYNE stock remaining volatile in recent days, any further data releases or business updates in this presentation could cause a big move in Zynerba shares.At the time of this writing, Ian Bezek held no positions in any of the aforementioned securities. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Are These 7 Dividend Aristocrats ETFs Fit for a King? * 7 of the Best Emerging Markets Stocks to Buy * 5 Gold Stocks That Should Glitter in 2019 Compare Brokers The post Zynerba Stock Is Marijuana-Adjacent Play Worth a Look appeared first on InvestorPlace.
- GlobeNewswire•3 months ago
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 50,000 shares of its common stock to a new employee, with a grant date of February 1, 2019. The options will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient's start date, and will vest and become exercisable as to the remaining 75 percent of the shares in 36 equal monthly installments at the end of each month following the anniversary, subject to the employee's continued employment with Marinus on such vesting dates. The stock options were granted as inducements material to the new employee entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.
- GlobeNewswire•4 months ago
New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis — Consolidated Revenues, Company Growth, and Expectations for 2019
NEW YORK, Jan. 30, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•4 months ago
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 105,000 shares of its common stock to five new employees, with a grant date of January 24, 2019. The options will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient's start date, and will vest and become exercisable as to the remaining 75 percent of the shares in 36 equal monthly installments at the end of each month following the anniversary, subject to the employee's continued employment with Marinus on such vesting dates. The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.
Insider Monkey•5 months agoHedge Funds Are Crazy About Marinus Pharmaceuticals Inc (MRNS)
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don’t make them change their opinion towards a company. This time it may be different. During the first 6 weeks of the fourth quarter we observed increased volatility and small-cap stocks underperformed […]
- American City Business Journals•5 months ago
Marinus Pharmaceuticals plans $45M stock sale
Based in Radnor, Marinus Pharmaceuticals is studying a potential treatment for postpartum depression and acute epilepsy.
- GlobeNewswire•5 months ago
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or the “Company”) announced the pricing of an underwritten public offering of 12,000,000 shares of common stock at a public offering price of $3.75 per share. The total public offering size is expected to be $45.0 million, before deducting the underwriting discounts and commissions and other offering expenses payable by the Company. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 1,800,000 shares of common stock.
- Motley Fool•5 months ago
Here's Why Marinus Pharmaceuticals Is Sinking Today
A secondary offering on the way isn't what investors wanted to hear.
- Benzinga•5 months ago
The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 11) Imprimis Pharmaceuticals Inc (NASDAQ: IMMY ) OvaScience ...
- GlobeNewswire•5 months ago
Marinus Pharmaceuticals Announces Public Offering of Common Stock
Marinus Pharmaceuticals, Inc. (MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Marinus. Jefferies LLC and Leerink Partners LLC are acting as joint bookrunning managers for the offering. Marinus also expects to grant the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- Benzinga•5 months ago
Marinus Pharma's Postpartum Depression Candidate Aces Midstage Trials
A handful of micro-cap stocks were making moves Monday, with the release of clinical trial results being the catalyst. Marinus said the Phase 2 trials that evaluated intravenous and oral ganaxolone for women with postpartum depression, or PPD, produced positive results.
- GlobeNewswire•5 months ago
Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression
Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV) (the Magnolia Study) and oral (the Amaryllis Study) in women with postpartum depression (PPD). Based on these results, the Company is advancing both studies into the next phase of development to evaluate IV and oral dose regimens.
